Filing Details

Accession Number:
0000919574-12-004032
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-06-18 14:58:52
Reporting Period:
2012-06-14
Filing Date:
2012-06-18
Accepted Time:
2012-06-18 14:58:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1124608 Response Genetics Inc RGDX In Vitro & In Vivo Diagnostic Substances (2835) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315309 Partnership Limited Partners Lansdowne 15 Davies Street
London X0 W1K 3AG
No No Yes No
1469444 Ltd Fund Master Investment Strategic Uk Lansdowne C/O Credit Suisse (Ireland) Ltd
Kilmore House, Park Lane, Spencer Dock
Dublin L2 DUBLIN 1
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.01 Per Share Disposition 2012-06-14 37,028 $1.25 3,814,608 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.01 Per Share 3,814,608 Indirect See footnote.
Footnotes
  1. These reported securities are held in the account of Lansdowne UK Strategic Investment Master Fund Limited (the "Master Fund") and may be deemed to be beneficially owned by Lansdowne Partners Limited Partnership by virtue of its role as the investment advisor of the Master Fund. Lansdowne Partners Limited Partnership disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that Lansdowne Partners Limited Partnership is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.